1. Clearance of buprenorphine during pregnancy and neonatal outcomes
- Author
-
Cody B McLeod, Xiaotong Han, Michael J. Mancino, Zachary N. Stowe, Shona L. Ray-Griffith, Jessica L Coker, and Gregory L Kearns
- Subjects
Pregnancy ,medicine.medical_specialty ,Dose ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,Opioid use disorder ,medicine.disease ,030226 pharmacology & pharmacy ,03 medical and health sciences ,Psychiatry and Mental health ,0302 clinical medicine ,Neonatal outcomes ,medicine ,Gestation ,030212 general & internal medicine ,medicine.symptom ,business ,Suicidal ideation ,Postpartum period ,Buprenorphine ,medicine.drug - Abstract
Buprenorphine is emerging as the preferred pharmacologic treatment for opioid use disorder during pregnancy. We examined the relative plasma clearance of buprenorphine (BUP) across pregnancy. Pregnant women with opioid use disorder participating in a prospective, observational study from 2013 to 2016 on stress in pregnancy who were receiving BUP for opioid use disorder were included. Women with an active eating disorder or suicidal ideation were excluded. Research visits occurred at 4–6-week intervals across pregnancy and the early postpartum period and included medication exposure history and blood samples. All assays for BUP serum concentrations at steady state were completed. Relative weight-adjusted clearance (Cl) was calculated using Cl = (daily dose [mg]/ body weight [kg])/serum concentration [ng/ml]. We collected 112 maternal blood samples from 29 women throughout pregnancy and the postpartum period. Serum concentrations for BUP ranged from
- Published
- 2021